1Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance.Diabetes Care, 2000,23: 650-657.
2Bruce DG, Storlien LH, Furler SM, et al. Cephalic phase metabolic responses in normal weight adults. Metabolism,1987,36:721-725.
3Brunzell JD, Robertson RP, Lerner RL, et al. Relationship between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance. J Clin Endocrinol Metab, 1976,42: 222-229.
4Andrew WJ, Vasquez B, Nagulesparan M, et al. Insulin therapy in obese non-insulin-dependent diabetes induces improvement in insulin action and secretion that maintained for twoweeks after insulin withdrawal. Diabetes, 1984,33: 634-642.
5Alvarsson M, Sundikvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care, 2003,26: 2231-2237.
6DeWitt DE, Hirsch IB. Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus Scientific Review. JAMA,2003,289: 2254-2264.
7Riddle MC, Ronsenstock J, Gerich J. The treat-to-target trial:Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003, 26:3080-3086.
8Yki-Jarvinen H. Combination therapy with insulin in type 2 diabetes. Diabetes Care,2001,24: 758-767.
